Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Gains from Investment Securities (2017 - 2021)

Cogent Biosciences has reported Gains from Investment Securities over the past 5 years, most recently at $3.7 million for Q3 2021.

  • Quarterly results put Gains from Investment Securities at $3.7 million for Q3 2021, up 277.96% from a year ago — trailing twelve months through Sep 2021 was $3.7 million (up 277.96% YoY), and the annual figure for FY2025 was $28.0 million, changed.
  • Gains from Investment Securities for Q3 2021 was $3.7 million at Cogent Biosciences, up from $3.4 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for COGT hit a ceiling of $4.3 million in Q2 2020 and a floor of -$5.2 million in Q4 2020.
  • Median Gains from Investment Securities over the past 5 years was $928389.5 (2018), compared with a mean of $1.2 million.
  • Peak annual rise in Gains from Investment Securities hit 200260.0% in 2020, while the deepest fall reached 6562.5% in 2020.
  • Cogent Biosciences' Gains from Investment Securities stood at $3.2 million in 2017, then grew by 16.0% to $3.7 million in 2018, then crashed by 97.82% to $80000.0 in 2019, then tumbled by 6562.5% to -$5.2 million in 2020, then skyrocketed by 171.88% to $3.7 million in 2021.
  • The last three reported values for Gains from Investment Securities were $3.7 million (Q3 2021), $3.4 million (Q2 2021), and $332757.0 (Q1 2021) per Business Quant data.